AMSTERDAM , July 20th 2016 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics. The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect™ and HydraSpace™, generate ADCs with significantly improved therapeutic index when compared directly to Kadcyla® and Adcetris®, the two FDA-approved ADCs for the treatment of Her2-positive breast cancer and multiple lymphoma indications, respectively.
“Improvement in the therapeutic index is a key metric in the quest for superior ADCs. What is exciting about our technology is that we can now consistently demonstrate in preclinical models of liquid and solid tumors that if we connect the same antibody and payload from each commercially-available ADC product using our proprietary technology, we are able to increase the efficacy of the drug as well as its safety and tolerability. These data confirm our experimental findings to date and highlight the potential of our technology to address the persistent unmet medical need across a wide variety of cancer types,” said Dr. Floris van Delft, CSO of Synaffix.
Together with this data, Synaffix today announced the expansion of its Scientific Advisory Board with the addition of Dr. George W. Sledge, the Chief of Medical Oncology at Stanford University Medical Center and former President of the American Society of Clinical Oncology.
“It is an honor to join the SAB at such an important time in the Company’s history. The preclinical data package of Synaffix has demonstrated, in multiple cancer types now, the ability of the technology to produce differentiated targeted cancer therapeutics. I look forward to further supporting the Company as it undertakes the translation of its platform technology into clinical ADC programs,” said Dr. Sledge.
GlycoConnect™ and HydraSpace™
The Synaffix technology platforms include GlycoConnect™, the site-specific and stable antibody conjugation technology that involves proprietary enzymes and metal-free click conjugation reagents, and HydraSpace™, the ADC-enhancing spacer technology. GlycoConnect™ was shown to be capable of significantly enhancing the therapeutic index of an ADC on its own. The highly polar properties of HydraSpace® improve the solubility and stability of the payload and the resulting ADC product, thus enhancing further the therapeutic index of the ADC. Both technologies have demonstrated compatibility with all ADC payload classes and all IgG isotypes without requiring antibody engineering.
About Synaffix BV
Founded in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on the continued advancement of best-in-class ADC technology platforms.
As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure™.
Synaffix is backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and Merck Ventures, the strategic corporate venture capital fund of Merck.
Director, Business Development